Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

Journal of Clinical Oncology

Volumn 27, Issue 27, 2009, Pages 4469-4474

  Di Lorenzo, Giuseppe ^a   Cartenì, Giacomo ^a   Autorino, Riccardo ^a   Bruni, Gianni ^a   Tudini, Marianna ^a   Rizzo, Mimma ^a   Aieta, Michele ^a   Gonnella, Antonio ^a   Rescigno, Pasquale ^a   Perdonà, Sisto ^a   Giannarini, Gianluca ^a   Pignata, Sandro ^a   Longo, Nicola ^a   Palmieri, Giovannella ^a   Imbimbo, Ciro ^a   De Laurentiis, Michele ^a   Mirone, Vincenzo ^a   Ficorella, Corrado ^a   De Placido, Sabino ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; SUNITINIB;

ADULT; AGED; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLEEDING; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEADACHE; HEART DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH INFLAMMATION; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; PYRROLES;

EID: 73749087933     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.6480     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics. Ca Cancer J Clin 56:106-130, 2006
2. Yagoda A, Bander NH: Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 44:338-345, 1989
3. Harris DT: Hormonal therapy and chemotherapy of renal cell carcinoma. Semin Oncol 10:422-430, 1983
4. Horoszewicz JS, Murphy GP: An assessment of the current use of human interferons in therapy of urological cancers. J Urol 142:1173-1180, 1989
5. Rosenberg SA, Yang JC, White DE, et al: Durability of complete responses in patients with metastatic cancer treated with high dose interleukin-2: Identification of antigens mediating response. Ann Surg 228:307-319, 1998
6. Hicklin DJ, Ellis LM: Role of vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027, 2005
7. Rini BI, Small EJ: Biology and clinical development of vascular endothelial growth-factor targeted therapy in renal cell carcinoma. J Clin Oncol 23: 1028-1043, 2005
8. Motzer RJ, Hutson TE, Tomczack P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
9. Escudier B, Eisen T, Stadler W, et al: Sorafenib in advanced clear-cell carcinoma. N Engl J Med 356:125-134, 2007
10. Mendel DB, Lard AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
11. Sablin MP, Bouaita L, Balleyguier C, et al: Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol 25:244s, 2007 (suppl; abstr 5038)
12. Eichelberg C, Heuer R, Chun FK, et al: Sequential use of tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: A retrospective outcome analysis. Eur Urol 54:1373-1378, 2008
13. Dudek AZ, Zolnierek J, Dham A, et al: Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115:61-67, 2009
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
15. National Cancer Institute: Common terminology criteria for adverse events v3.0. http://ctep.cancer.gov/reporting/ctc.html
16. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004
17. Mizukami Y, Kohgo Y, Chung DC: Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res 13:5670-5674, 2007
18. Caraglia M, Tassone P, Marra M, et al: Targeting Raf-kinase: Molecular rationales and translational issues. Ann Oncol 17:viii124-viii127, 2006 (suppl 7)
19. Di Lorenzo G, Autorino R, Bruni G, et al: Cardiovascular toxicity after sunitinib therapy in metastatic renal cell cancer: A multicenter analysis. Ann Oncol doi: 10.1093/annonc/mdp025
20. Tamaskar I, Garcia JA, Elson P, et al: Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179:81-86, 2008
21. Rixe O, Bukowski RM, Michaelson MD, et al: Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study. Lancet Oncol 8:975-984, 2007
22. Rini BI, Michaelson MD, Rosenberg JE, et al: Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26:3743-3748, 2008
23. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
24. National Institutes of Health: Protocols: (NCT00474786) and (NCT00782275). http://clinicaltrials.gov/